Optimizing Acute Migraine Treatment

Introduction to Optimized Treatment Strategies

The American College of Physicians recommends combining rizatriptan 10 mg with a fast-acting NSAID, such as naproxen sodium 500 mg or ibuprofen 400-800 mg, taken simultaneously at migraine onset, as this combination provides superior efficacy compared to either agent alone 1
The American Academy of Neurology suggests that the NSAID component prevents the 40% recurrence rate that occurs within 48 hours after apparently successful triptan treatment 2

The American Headache Society recommends prescribing rizatriptan 10 mg plus naproxen sodium 500 mg taken together at the first sign of migraine, as this combination results in 130 more patients per 1000 achieving sustained pain relief at 48 hours compared to triptan monotherapy 1
The European Neurological Society states that timing is critical, and both medications must be taken early in the attack while the headache is still mild for maximum effectiveness 2, 3

The American College of Physicians advises strictly limiting all acute migraine medications to no more than 2 days per week to prevent medication-overuse headache, which paradoxically increases headache frequency and can lead to daily headaches 1, 4
The American Academy of Neurology recommends that for triptans specifically, the threshold is ≥10 days per month, and for NSAIDs, it's ≥15 days per month 1

The European Neurological Society suggests switching to a different triptan formulation, as failure of one triptan does not predict failure of others 2, 4
The American Headache Society recommends considering sumatriptan 100 mg or eletriptan as alternatives, since rizatriptan already represents one of the faster-acting oral options 3

The American Academy of Neurology recommends immediately initiating preventive therapy if the patient requires acute treatment more than 2 days per week or continues to have impaired quality of life despite optimized acute therapy 2, 4, 5
The American College of Physicians suggests first-line preventive options, including propranolol 80-240 mg/day, topiramate, or divalproex sodium, and amitriptyline 30-150 mg/day 4

The American College of Physicians advises against prescribing opioids or butalbital for acute migraine treatment, as they have questionable efficacy, considerable adverse effects, risk of dependency, and lead to rebound headaches 1, 3, 5
The European Neurological Society recommends avoiding oral ergot alkaloids, as they are poorly effective and potentially toxic 3, 5